We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT<sub>1</sub>R Modulator for the Treatment of Metabolic Fatty Liver Disease.
- Authors
Fiorucci, Stefano; Rapacciuolo, Pasquale; Fiorillo, Bianca; Roselli, Rosalinda; Marchianò, Silvia; Di Giorgio, Cristina; Bordoni, Martina; Bellini, Rachele; Cassiano, Chiara; Conflitti, Paolo; Catalanotti, Bruno; Limongelli, Vittorio; Sepe, Valentina; Biagioli, Michele; Zampella, Angela
- Abstract
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are two highly prevalent human diseases caused by excessive fat deposition in the liver. Although multiple approaches have been suggested, NAFLD/NASH remains an unmet clinical need. Here, we report the discovery of a novel class of hybrid molecules designed to function as cysteinyl leukotriene receptor 1 (CysLT1R) antagonists and G protein bile acid receptor 1 (GPBAR1/TGR5) agonists for the treatment of NAFLD/NASH. The most potent of these compounds generated by harnessing the scaffold of the previously described CystLT1R antagonists showed efficacy in reversing liver histopathology features in a preclinical model of NASH, reshaping the liver transcriptome and the lipid and energy metabolism in the liver and adipose tissues. In summary, the present study described a novel orally active dual CysLT1R antagonist/GPBAR1 agonist that effectively protects against the development of NAFLD/NASH, showing promise for further development.
- Subjects
FATTY liver; FARNESOID X receptor; NON-alcoholic fatty liver disease; ADIPOSE tissues; G proteins
- Publication
Frontiers in Pharmacology, 2022, Vol 13, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2022.858137